MNCs gain ground in China’s centralized procurement

Five multinational originator companies were among the winning bidders in China’s national expansion of its centralized procurement program for generic and off-patent drugs in a process that saw steep price cuts and more robust participation by Western companies compared with last year’s pilot.

The list of winning bidders released by China’s Joint Procurement Office on Wednesday also marked the entrance of global generics companies, including the first winning bid by an Indian company.

Under

Read the full 722 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE